Recent advances in managing axial spondyloarthritis

Priyanka Agrawal; Pedro M Machado

doi:10.12688/f1000research.22577.1

Recent advances in managing axial spondyloarthritis

F1000Res. 2020 Jul 13:9:F1000 Faculty Rev-697. doi: 10.12688/f1000research.22577.1. eCollection 2020.

Authors

Priyanka Agrawal¹, Pedro M Machado^{1

2

3}

Affiliations

¹ Department of Rheumatology, Northwick Park Hospital, London North West University NHS Trust, London, UK.
² Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK.
³ Centre for Rheumatology, Division of Medicine & Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, UK.

Abstract

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that predominantly affects the axial skeleton. The advent of biologic drugs has transformed the management of patients with axSpA. However, non-steroidal anti-inflammatory drugs remain the first-line drug treatment for axSpA. The optimal management of patients with axSpA requires a combination of pharmacological and non-pharmacological treatment modalities, namely exercise and physical therapy. This review looks at novel therapeutic options in patients with axSpA. It also summarises current evidence regarding radiographic progression and treat-to-target in axSpA.

Keywords: Axial spondyloartrhitis; ankylosing spondylitis; biologics; management; outcomes.; treatment.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Disease Progression
Humans
Spondylarthritis* / therapy
Spondylitis, Ankylosing*

Grants and funding

DH_/Department of Health/United Kingdom